Efficacy and Safety of Glucagon‐Like Peptide 1 Receptor Agonists in Parkinson Disease: A Systematic Review and Meta‐Analysis

Current evidence does not demonstrate a statistically significant overall benefit of GLP-1RAs on efficacy outcomes in PD, while gastrointestinal adverse events are increased. More trials are needed to clarify their disease-modifying potential.